Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239797 | 1.00 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPK1SMN1; SMN2APEX1 | |
| SCHEMBL781957 | 0.87 | DDR1 (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2APEX1 | |
| SCHEMBL781955 | 0.87 | DDR1 (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2APEX1 | |
| SCHEMBL29798955 | 0.87 | DDR1 (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2APEX1 | |
| SCHEMBL781954 | 0.86 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPK1SMN1; SMN2ENPP2 | |
| SCHEMBL781952 | 0.86 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPK1SMN1; SMN2ENPP2 | |
| SCHEMBL781524 | 0.86 | ALDH1A1 (0.38) | ALDH1A1LMNAMAPK1SMN1; SMN2ENPP2 | |
| SCHEMBL781526 | 0.86 | ALDH1A1 (0.38) | ALDH1A1LMNAMAPK1SMN1; SMN2ENPP2 | |
| SCHEMBL29798818 | 0.86 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPK1SMN1; SMN2ENPP2 | |
| SCHEMBL29798819 | 0.86 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPK1SMN1; SMN2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | claimed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | claimed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | claimed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3424534-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190125674-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-02 | — | — | US | disclosed |
| US-10206877-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885LMNA 2950/4885MAPK1 2369/4885 |
| US-20190125674-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885LMNA 2950/4885MAPK1 2369/4885 |
| US-10206877-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.